Resultados de búsqueda - ".br" :: Descubridor de recursos de la Universidad Veracruzana

1801

Effect on Local Structure and Phase Transition of Perovskite-Type [N(CH(3))(4)](2)Zn(1-x)Cu(x)Br(4) (x = 0, 0.5, 0.7, and 1) Crystals with the Various Doping of Cu(2+) Ions

por Lim, Ae Ran
Publicado 2018

“…This study focused on how the local structures in pure [N(CH(3))(4)](2)ZnBr(4) crystal are affected by the partial replacement of Zn(2+) ions with Cu(2+) ions. …”

Enlace del recurso
Enlace del recurso
Enlace del recurso

Online Artículo Texto

Cargando…

Effect on Local Structure and Phase Transition of Perovskite-Type [N(CH(3))(4)](2)Zn(1-x)Cu(x)Br(4) (x = 0, 0.5, 0.7, and 1) Crystals with the Various Doping of Cu(2+) Ions

1802

Impact of Humidity and Temperature on the Stability of the Optical Properties and Structure of MAPbI(3), MA(0.7)FA(0.3)PbI(3) and (FAPbI(3))(0.95)(MAPbBr(3))(0.05) Perovskite Thin Films

por Tumusange, Marie Solange, Subedi, Biwas, Chen, Cong, Junda, Maxwell M., Song, Zhaoning, Yan, Yanfa, Podraza, Nikolas J.
Publicado 2021

“…In situ real-time spectroscopic ellipsometry (RTSE) measurements have been conducted on MAPbI(3), MA(0.7)FA(0.3)PbI(3), and (FAPbI(3))(0.95)(MAPbBr(3))(0.05) perovskite thin films when exposed to different levels of relative humidity at given temperatures over time. …”

Enlace del recurso
Enlace del recurso
Enlace del recurso

Online Artículo Texto

Cargando…

Impact of Humidity and Temperature on the Stability of the Optical Properties and Structure of MAPbI(3), MA(0.7)FA(0.3)PbI(3) and (FAPbI(3))(0.95)(MAPbBr(3))(0.05) Perovskite Thin Films

1803

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

por Nowakowski, Grzegorz S., Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Peters, Anthea, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Sabatelli, Lorenzo, Waltl, Eva E., Winderlich, Mark, Sporchia, Andrea, Kurukulasuriya, Nuwan C., Cordoba, Raul, Hess, Georg, Salles, Gilles
Publicado 2023

“…A significant OS benefit was observed with tafasitamab+lenalidomide versus pola-BR (HR: 0.441; p = 0.034) and R2 (HR: 0.435; p = 0.012). …”

Enlace del recurso
Enlace del recurso
Enlace del recurso

Online Artículo Texto

Cargando…

$RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma$

1804

Assessment of Safety and Effectiveness of the Extracorporeal Continuous-Flow Ventricular Assist Device (BR16010) Use as a Bridge-to-Decision Therapy for Severe Heart Failure or Refractory Cardiogenic Shock: Study Protocol for Single-Arm Non-randomized, Uncontrolled, and Investigator-Initiated Clinical Trial

por Fukushima, Norihide, Tatsumi, Eisuke, Seguchi, Osamu, Takewa, Yoshiaki, Hamasaki, Toshimitsu, Onda, Kaori, Yamamoto, Haruko, Hayashi, Teruyuki, Fujita, Tomoyuki, Kobayashi, Junjiro
Publicado 2018

“…The purpose of this study (NCVC-BTD_01, National Cerebral and Cardiovascular Center-Bridge to Dicision_01) is to assess the safety and effectiveness of the newly developed extracorporeal continuous-flow ventricular assist system employing a disposable centrifugal pump with a hydrodynamically levitated bearing (BR16010) use as a bridge-to-decision therapy for patients with severe heart failure or refractory cardiogenic shock. …”

Enlace del recurso
Enlace del recurso
Enlace del recurso

Online Artículo Texto

Cargando…

$Assessment of Safety and Effectiveness of the Extracorporeal Continuous-Flow Ventricular Assist Device (BR16010) Use as a Bridge-to-Decision Therapy for Severe Heart Failure or Refractory Cardiogenic Shock: Study Protocol for Single-Arm Non-randomized, Uncontrolled, and Investigator-Initiated Clinical Trial$

1805

Crystal structure and magnetic study of the complex salt [RuCp(PTA)(2)–μ-CN-1κC:2κN–RuCp(PTA)(2)][Re(NO)Br(4)(EtOH)(0.5)(MeOH)(0.5)]

por Pacheco, Mario, Alvarez, Natalia, Cuevas, Alicia, Romerosa, Antonio, Lloret, Francesc, Kremer, Carlos
Publicado 2021

“…A new Ru(II)–Re(II) complex salt, μ-cyanido-κ(2) C:N-bis[(η(5)-cyclopentadienyl)bis(3,5,7-triazaphosphaadamantane-κP)ruthenium(II)] tetrabromido(ethanol/methanol-κO)nitrosylrhenate(II), [Ru(CN)(C(5)H(5))(2)(C(6)H(12)N(3)P)(4)][ReBr(4)(NO)(CH(4)O)(0.5)(C(2)H(6)O)(0.5)] or [RuCp(PTA)(2)–μ-CN–1κC:2κ(2) N-RuCp(PTA)(2)][Re(NO)Br(4)(EtOH)(0.5)(MeOH)(0.5)] (PTA = 3,5,7-triazaphosphaadamantane) was obtained and characterized by single-crystal X-ray diffraction, elemental analysis and infrared spectroscopy. …”

Enlace del recurso
Enlace del recurso
Enlace del recurso

Online Artículo Texto

Cargando…

Crystal structure and magnetic study of the complex salt [RuCp(PTA)(2)–μ-CN-1κC:2κN–RuCp(PTA)(2)][Re(NO)Br(4)(EtOH)(0.5)(MeOH)(0.5)]

1806

In Vitro Tests for a Rapid Evaluation of Antidiabetic Potential of Plant Species Containing Caffeic Acid Derivatives: A Validation by Two Well-Known Antidiabetic Plants, Ocimum gratissimum L. Leaf and Musanga cecropioides R. Br. ex Tedlie (Mu) Stem Bark

por Awwad, Abdulmomem, Poucheret, Patrick, Idres, Yanis A., Tshibangu, Damien S. T., Servent, Adrien, Ferrare, Karine, Lazennec, Françoise, Bidel, Luc P. R., Cazals, Guillaume, Tousch, Didier
Publicado 2021

“…(Oc) leaf extract and Musanga cecropoides R. Br. ex Tedlie (Mu) stem bark extract. Chemical compositions were analyzed by LCMS and HPLC. …”

Enlace del recurso
Enlace del recurso
Enlace del recurso

Online Artículo Texto

Cargando…